Dicerna pharmaceuticals ceo
WebMay 15, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ETExecutivesDouglas Fambrough - Co-Founder, CEO, … WebAug 11, 2024 · President and CEO of Dicerna Pharmaceuticals Inc (30-Year Financial, Insider Trades) Douglas Fambrough (insider trades) bought 5,000 shares of DRNA on …
Dicerna pharmaceuticals ceo
Did you know?
WebApr 4, 2024 · Aradhye, who is returning to Novartis, was most recently Executive Vice President and Chief Medical Officer at Dicerna Pharmaceuticals where he led the development of multiple clinical stage RNAi assets. ... CEO Novartis. “I would like to congratulate Marie-France, Shreeram, Steffen and Victor on their new roles, and extend … WebAug 10, 2024 · The estimated net worth of Douglas Fambrough is at least $852,306.00 as of September 1st, 2024. Dr. Fambrough owns 22,300 shares of Dicerna Pharmaceuticals stock worth more than $852,306 as of April 10th. This net worth evaluation does not reflect any other assets that Dr. Fambrough may own.
WebDec 25, 2024 · The CEO and management are extremely transparent. The benefits package is generous and reflects the fact that employees are valued and appreciated. Cons. As with any biotech, work is fast paced and can be unpredictable. But Dicerna does a good job of helping employees keep a good work life balance. WebJun 24, 2024 · The estimated Net Worth of Douglas Fambrough is at least $17.7 Million dollars as of 15 December 2024. Douglas Fambrough owns over 13,750 units of Dicerna Pharmaceuticals Inc stock worth over $9,049,693 and over the last 9 years he sold DRNA stock worth over $3,614,546. In addition, he makes $5,048,130 as President, Chief …
WebJan 17, 2024 · 100% Approve of CEO. Found 3 of over 64 reviews. Sort. Popular. Popular; COVID-19 Related; ... Glassdoor has 64 Dicerna Pharmaceuticals reviews submitted anonymously by Dicerna Pharmaceuticals employees. Read employee reviews and ratings on Glassdoor to decide if Dicerna Pharmaceuticals is right for you. WebFeb 28, 2024 · Dicerna Pharmaceuticals, Inc. (DRNA) Q4 2024 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Lauren Stival – Stern Investor Relations, Inc.
WebMay 28, 2024 · Our data indicates that Dicerna Pharmaceuticals, Inc. has a market capitalization of US$2.4b, and total annual CEO compensation was reported as US$6.6m for the year to December 2024. Notably, that ...
hardwood olympiaWebFounded: 2007. Type: Company - Public (DRNA) Industry: Biotech & Pharmaceuticals. Revenue: Unknown / Non-Applicable. Competitors: Unknown. Dicerna is working to improve the lives of people suffering from diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. hardwood okla cityWebHumbled to be a part of this enriching discussion with some of the most amazing women of NN! ̈ #iwd2024 #diversityequityinclusion #novonordisk… changes in chromosome numberWebDicerna Pharmaceuticals, Inc. 30,350 followers on LinkedIn. Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to ... hardwood on concrete basement floorWebSep 2, 2024 · President and CEO of Dicerna Pharmaceuticals Inc (30-Year Financial, Insider Trades) Douglas Fambrough (insider trades) bought 10,000 shares of DRNA on … hardwood on slab foundationWebProvided support to the CEO and the Director of Operations Regional Administrative Assistant Pfizer Pharmaceuticals Apr 2005 - Jan ... Sr. … changes in cigarette lawWebCEO: Douglas M. Fambrough. Employees: 78. 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE, MA 02140 617 621 8097. www.dicerna.com ... DICERNA PHARMACEUTICALS INC DRNA: 2024-12-28 12:45:03 UTC-0.2091: 0.2891: 250000: Current Active Short Positions. Holder Issuer Net Short Position Position Date Origin; changes in chromosome structure